BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy

Meckbach, Diana, Keim, Ulrike, Richter, Sabina, Leiter, Ulrike, Eigentler, Thomas K., Bauer, Jürgen, Pflugfelder, Annette, Büttner, Petra, Garbe, Claus, and Weide, Benjamin (2014) BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy. PLoS ONE, 9 (2). e89218. pp. 1-7.

[img]
Preview
PDF (Published Version) - Published Version
Available under License Creative Commons Attribution.

Download (375kB) | Preview
View at Publisher Website: http://dx.doi.org/10.1371/journal.pone.0...
 
16
43


Abstract

Background

The impact of BRAF tumor mutations on the natural course of disease of melanoma patients is controversial.

Patients and Methods

We analyzed the mutational status and overall survival of 215 patients receiving treatment with dacarbazine or temozolomide. All patients who started first-line treatment at our institution between 2000 and 2010 were included to prevent selection and bias due to thereafter arising therapeutic options.

Results

No patient received BRAF- or MEK-inhibitors during follow-up. Survival was associated with the pattern of visceral involvement, the presence of brain metastases and the serum lactate dehydrogenase level (all p<0.001). The BRAF-V600 mutational status was not associated with survival and no differences in overall survival were detected according to age, gender or to the cytotoxic agent used for therapy. In Cox regression analysis the presence of brain metastases (hazard ratio 2.3; p<0.001) and an elevated serum LDH (hazard ratio 2.5; p<0.001) were the only factors, which independently predicted survival.

Conclusions

No differences in prognosis were observed according to the BRAF mutational status in patients with distant metastasis treated with monochemotherapy.

Item ID: 32965
Item Type: Article (Research - C1)
ISSN: 1932-6203
Additional Information:

© 2014 Meckbach et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funders: Roche Pharma AG
Date Deposited: 30 Apr 2014 09:23
Downloads: Total: 43
Last 12 Months: 10
More Statistics

Actions (Repository Staff Only)

Item Control Page Item Control Page